Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Merus N.V.
MRUS
$95.88
Name : Merus N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,272,226,816.00
EPSttm : -5.28
finviz dynamic chart for MRUS
Merus N.V.
$95.88
0.07%
$0.07

Float Short %

2.5

Margin Of Safety %

Put/Call OI Ratio

1.31

EPS Next Q Diff

-0.1

EPS Last/This Y

-2.07

EPS This/Next Y

0.81

Price

95.9

Target Price

97

Analyst Recom

2.76

Performance Q

50.64

Relative Volume

0.71

Beta

1.06

Ticker: MRUS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20MRUS94.441.080.5944405
2025-10-21MRUS94.61.080.7744701
2025-10-22MRUS94.411.103.4846440
2025-10-23MRUS94.441.122.0447081
2025-10-24MRUS94.871.2213.4050071
2025-10-27MRUS94.551.320.4252542
2025-10-28MRUS94.921.326.3052524
2025-10-29MRUS94.861.321.9853192
2025-10-30MRUS95.061.33106.6753501
2025-10-31MRUS94.871.3513.2553798
2025-11-03MRUS94.81.350.3853828
2025-11-04MRUS95.041.3415.0054103
2025-11-05MRUS95.191.342.6954109
2025-11-06MRUS95.161.340.7354123
2025-11-07MRUS95.231.340.0254054
2025-11-10MRUS95.441.2831.9354966
2025-11-11MRUS95.51.280.7654886
2025-11-12MRUS96.041.290.5054708
2025-11-13MRUS96.061.290.2854988
2025-11-14MRUS95.981.316.8054560
2025-11-17MRUS95.91.314.2654697
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20MRUS94.446.5-17.3-5.60
2025-10-21MRUS94.606.5-20.0-5.60
2025-10-22MRUS94.406.5-18.4-5.60
2025-10-23MRUS94.436.5-19.4-5.60
2025-10-24MRUS94.886.5-21.3-5.60
2025-10-27MRUS94.596.5-18.0-5.60
2025-10-28MRUS94.906.5-20.6-5.62
2025-10-29MRUS94.866.5-19.1-5.62
2025-10-30MRUS95.066.5-20.4-5.62
2025-10-31MRUS94.866.5-18.5-5.62
2025-11-03MRUS94.806.5-19.1-5.62
2025-11-04MRUS95.04-155.80.5-5.76
2025-11-05MRUS95.19-155.80.9-5.76
2025-11-06MRUS95.15-84.22.1-5.30
2025-11-07MRUS95.23-84.21.6-5.30
2025-11-10MRUS95.42-84.21.1-5.30
2025-11-11MRUS95.48-94.21.8-5.42
2025-11-12MRUS96.03-94.2-0.4-5.42
2025-11-13MRUS96.07-94.21.7-5.42
2025-11-14MRUS95.98-94.22.4-5.42
2025-11-17MRUS95.90-94.22.4-5.42
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20MRUS-1.073.994.26
2025-10-21MRUS-1.073.994.26
2025-10-22MRUS-1.073.994.26
2025-10-23MRUS-1.073.994.26
2025-10-24MRUS-1.073.994.26
2025-10-27MRUS-1.074.093.25
2025-10-28MRUS-1.074.093.25
2025-10-29MRUS-1.074.093.25
2025-10-30MRUS-1.074.093.25
2025-10-31MRUS-1.074.093.25
2025-11-03MRUS-1.074.043.25
2025-11-04MRUS-1.074.043.25
2025-11-05MRUS-1.074.043.25
2025-11-06MRUS-1.074.043.25
2025-11-07MRUS-1.074.043.25
2025-11-10MRUS-1.07-4.023.25
2025-11-11MRUS-1.07-4.023.25
2025-11-12MRUS-1.07-4.022.50
2025-11-13MRUS-1.07-4.022.50
2025-11-14MRUS-1.07-4.022.50
2025-11-17MRUS-1.07-3.362.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.23

Avg. EPS Est. Current Quarter

-0.95

Avg. EPS Est. Next Quarter

-1.33

Insider Transactions

-1.07

Institutional Transactions

-3.36

Beta

1.06

Average Sales Estimate Current Quarter

8

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

19

Growth Score

36

Sentiment Score

89

Actual DrawDown %

0.4

Max Drawdown 5-Year %

-60.4

Target Price

97

P/E

Forward P/E

PEG

P/S

128.46

P/B

9.38

P/Free Cash Flow

EPS

-5.33

Average EPS Est. Cur. Y​

-5.42

EPS Next Y. (Est.)

-4.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-673.31

Relative Volume

0.71

Return on Equity vs Sector %

-76.1

Return on Equity vs Industry %

-61.2

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

2.4
Merus N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 260
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
stock quote shares MRUS – Merus N.V Stock Price stock today
news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch MRUS – Merus N.V yahoo finance google finance
stock history MRUS – Merus N.V invest stock market
stock prices MRUS premarket after hours
ticker MRUS fair value insiders trading